HeartFlow Analysis vs EchoNext
AI Verdict
Choose HeartFlow Analysis if…
Choose HeartFlow Analysis if you need a highly detailed, non-invasive assessment of coronary artery disease (CAD) that goes beyond anatomical imaging to evaluate blood flow impact. This tool is ideal for patients with suspected CAD, especially those with inconclusive stress tests or who wish to avoid unnecessary invasive procedures, as it provides personalized 3D models and Fractional Flow Reserve derived from CT (FFRct) analysis to guide treatment decisions.
View HeartFlow Analysis →Choose EchoNext if…
Choose EchoNext if you require an accessible, AI-powered screening tool to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs. This tool is particularly well-suited for broad implementation in various clinical settings, from major hospitals to community practices, to identify high-risk patients who warrant further evaluation with an echocardiogram.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | HeartFlow Analysis | EchoNext |
|---|---|---|
| Pricing | Contact vendor for pricing | Starts at $600/month |
| Deployment | Cloud-based (AWS) | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth HeartFlow Analysis and EchoNext aim to integrate seamlessly into existing clinical workflows. HeartFlow delivers analyses via a secure web interface and supports integration with PACS, EMR, and other IT solutions. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a large number of US clinicians, suggesting a focus on ease of access within existing physician tools.
Clinical Value
HeartFlow AnalysisHeartFlow Analysis has extensive clinical validation with over 200 studies assessing over 365,000 patients, demonstrating high diagnostic accuracy and improving clinical outcomes by guiding revascularization decisions and allowing safe deferral of invasive procedures. EchoNext has also shown high accuracy in detecting structural heart disease from ECGs, even outperforming cardiologists in studies, and has been credited with leading to the first AI-triggered heart transplant. However, HeartFlow's broader range of analyses (FFRct, plaque analysis, roadmap analysis) and longer history of extensive validation across various aspects of CAD diagnosis and management give it a slight edge in overall clinical value.
Pricing & Value
EchoNextEchoNext offers transparent tiered pricing starting at $600/month, with options for different organizational sizes and an annual discount. HeartFlow Analysis uses a fee-for-service model and requires contacting the vendor for specific pricing, although it is covered by Medicare and most US commercial payers with established CPT codes and payment rates. EchoNext's clear pricing structure provides better transparency and predictability for potential users.
Enterprise Readiness
HeartFlow AnalysisHeartFlow Analysis has been adopted by over 1,800 institutions globally and has robust support for technology integration with PACS, EMR, and other IT solutions, along with comprehensive billing and reimbursement support. EchoNext, while partnering with OpenEvidence for broad clinician access, is a newer offering with a more recent seed funding round to support expansion, suggesting HeartFlow has a more established enterprise footprint and support infrastructure.
Innovation
HeartFlow AnalysisHeartFlow has a longer track record of innovation, having developed AI-powered 3D modeling, FFRct analysis, and plaque analysis, with continuous improvements and new product introductions like Roadmap Analysis and PCI Navigator. EchoNext is innovative in its ability to detect multiple structural heart diseases from standard ECGs, a novel application that has received significant attention. However, HeartFlow's comprehensive suite of tools covering anatomical, physiological, and plaque assessment from CT scans represents a more extensive and continuously evolving innovative platform in cardiac diagnostics.
Support & Docs
HeartFlow AnalysisHeartFlow offers comprehensive support including hands-on training, technology integration, expert coding and reimbursement support, peer mentorship, and educational/marketing materials. While EchoNext is available through a widely used clinical decision support platform, detailed information on its specific support and documentation offerings beyond its integration is not as extensively documented as HeartFlow's.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | HeartFlow Analysis | EchoNext |
|---|---|---|
| Name | HeartFlow Analysis | EchoNext |
| Company | HeartFlow | Pathway Labs |
| Description | Software and AI designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans. | AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | AI-powered 3D modeling of coronary arteries, Fractional Flow Reserve derived from CT (FFRct) analysis, Plaque Analysis (quantification and characterization), Roadmapu2122 Analysis for CCTA reading, Non-invasive diagnostic assessment, Personalized patient insights, Computational Fluid Dynamics (CFD) for blood flow simulation, High diagnostic accuracy. | AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support. |
Videos
Demos, reviews, and walkthroughs featuring HeartFlow Analysis and EchoNext.